HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA

Executive Summary

Genentech/OSI's Tarceva, Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first three products approved under the "continuous marketing application" pilot program
Advertisement

Related Content

Macugen Access Program Will Help Seniors With Medicare Copay
Macugen Access Program Will Help Seniors With Medicare Copay
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
FDA Credibility Crisis: 1990 Generic Drug Scandal May Be Blueprint For 2005
FDA Credibility Crisis: 1990 Generic Drug Scandal May Be Blueprint For 2005
Amgen Kepivance To Launch In January; Additional Mucositis Trials Underway

Topics

Advertisement
UsernamePublicRestriction

Register

PS045203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel